Cited 4 times in
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김건민 | - |
dc.contributor.author | 김승일 | - |
dc.contributor.author | 박세호 | - |
dc.contributor.author | 박형석 | - |
dc.contributor.author | 박형순 | - |
dc.contributor.author | 백순명 | - |
dc.contributor.author | 손주혁 | - |
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2018-07-20T07:29:11Z | - |
dc.date.available | 2018-07-20T07:29:11Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160211 | - |
dc.description.abstract | PURPOSE: Trastuzumab-based treatment is the standard care for patients with HER2+ metastatic breast cancer (MBC). About 10% of HER2+ MBC showed a long-term durable response (progression-free survival, PFS > 3 years) to trastuzumab-based therapy. The aim of this study is to identify clinico-pathologic factors for a durable response to trastuzumab-based therapy in HER2-positive MBC. METHODS: In the Yonsei Breast Cancer MBC Database, we identified 1218 MBC patients who were diagnosed from 2006 to 2015. Among them, 294 had HER2+ disease, and 153 received trastuzumab plus taxane chemotherapy as first-line treatment. Clinico-pathologic factors, such as hormone receptor (HR) status and metastatic sites, were reviewed. To evaluate a durable response, landmark analysis was performed. RESULTS: The median follow-up time was 28 months (95% CI 4.4-83.0 months). Of 153 HER2+ patients, there were 73 HR- patients (47.7%), and bone was the most common metastatic site. The median PFS and overall survival (OS) were 12 and 39 months, respectively. HR- patients showed a tendency toward longer PFS (median, 13 vs. 11 months, P = 0.160) compared with HR+ patients. Patients with non-visceral metastases had longer median PFS and OS than those with visceral disease (median PFS, 15 vs. 11 months, P = 0.012; median OS, 75 vs. 34 months, P = 0.03). Landmark analysis at 9 months suggested that the PFS of HR- patients was significantly longer than that of HR+ patients (median, 19 vs. 9 months, P = 0.008). CONCLUSIONS: Among patients with HER2+ MBC, HR status is a possible predictive biomarker of a durable response to trastuzumab-based therapy. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Kluwer Academic | - |
dc.relation.isPartOf | BREAST CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/pharmacology | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Bone Neoplasms/drug therapy | - |
dc.subject.MESH | Bone Neoplasms/metabolism* | - |
dc.subject.MESH | Bone Neoplasms/mortality | - |
dc.subject.MESH | Bone Neoplasms/secondary | - |
dc.subject.MESH | Breast Neoplasms/drug therapy | - |
dc.subject.MESH | Breast Neoplasms/metabolism* | - |
dc.subject.MESH | Breast Neoplasms/mortality | - |
dc.subject.MESH | Breast Neoplasms/pathology | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Paclitaxel/administration & dosage | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Receptor, ErbB-2/metabolism* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Taxoids/administration & dosage uzumab/administration & dosage Treatment Outcome | - |
dc.title | Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Hyung Soon Park | - |
dc.contributor.googleauthor | Joohyuk Sohn | - |
dc.contributor.googleauthor | Seung Il Kim | - |
dc.contributor.googleauthor | Seho Park | - |
dc.contributor.googleauthor | Hyung Seok Park | - |
dc.contributor.googleauthor | Seul Ghi Gho | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Soonmyung Paik | - |
dc.contributor.googleauthor | Gun Min Kim | - |
dc.identifier.doi | 10.1007/s10549-017-4175-y | - |
dc.contributor.localId | A00287 | - |
dc.contributor.localId | A00658 | - |
dc.contributor.localId | A01524 | - |
dc.contributor.localId | A01753 | - |
dc.contributor.localId | A04576 | - |
dc.contributor.localId | A01823 | - |
dc.contributor.localId | A01995 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00403 | - |
dc.identifier.eissn | 1573-7217 | - |
dc.identifier.pmid | 28243895 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs10549-017-4175-y | - |
dc.subject.keyword | Durable response | - |
dc.subject.keyword | Hormone receptor status | - |
dc.subject.keyword | Landmark analysis | - |
dc.subject.keyword | Trastuzumab | - |
dc.contributor.alternativeName | Kim, Gun Min | - |
dc.contributor.alternativeName | Kim, Seung Il | - |
dc.contributor.alternativeName | Park, Se Ho | - |
dc.contributor.alternativeName | Park, Hyung Seok | - |
dc.contributor.alternativeName | Park, Hyung Soon | - |
dc.contributor.alternativeName | Paik, Soon Myung | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Kim, Gun Min | - |
dc.contributor.affiliatedAuthor | Kim, Seung Il | - |
dc.contributor.affiliatedAuthor | Park, Se Ho | - |
dc.contributor.affiliatedAuthor | Park, Hyung Seok | - |
dc.contributor.affiliatedAuthor | Park, Hyung Soon | - |
dc.contributor.affiliatedAuthor | Paik, Soon Myung | - |
dc.contributor.affiliatedAuthor | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.citation.volume | 163 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 255 | - |
dc.citation.endPage | 262 | - |
dc.identifier.bibliographicCitation | BREAST CANCER RESEARCH AND TREATMENT, Vol.163(2) : 255-262, 2017 | - |
dc.identifier.rimsid | 39067 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.